BE887518A - Cartothioates d'androstanes - Google Patents

Cartothioates d'androstanes

Info

Publication number
BE887518A
BE887518A BE0/203794A BE203794A BE887518A BE 887518 A BE887518 A BE 887518A BE 0/203794 A BE0/203794 A BE 0/203794A BE 203794 A BE203794 A BE 203794A BE 887518 A BE887518 A BE 887518A
Authority
BE
Belgium
Prior art keywords
cartothioates
androstan
androstan cartothioates
Prior art date
Application number
BE0/203794A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BE887518A publication Critical patent/BE887518A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0038—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 with an androstane skeleton, including 18- or 19-substituted derivatives, 18-nor derivatives and also derivatives where position 17-beta is substituted by a carbon atom not directly bonded to a further carbon atom and not being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE0/203794A 1980-02-15 1981-02-13 Cartothioates d'androstanes BE887518A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8005174 1980-02-15

Publications (1)

Publication Number Publication Date
BE887518A true BE887518A (fr) 1981-08-13

Family

ID=10511390

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/203794A BE887518A (fr) 1980-02-15 1981-02-13 Cartothioates d'androstanes

Country Status (8)

Country Link
US (1) US4335121A (fr)
JP (1) JPS56138200A (fr)
BE (1) BE887518A (fr)
CA (1) CA1201114A (fr)
EC (1) ECSP941097A (fr)
PH (1) PH24267A (fr)
ZA (1) ZA81976B (fr)
ZW (1) ZW18081A1 (fr)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861765A (en) * 1985-06-26 1989-08-29 Jouveinal 21-alkyl-, cycloalkyl- or aryl-substituted thio steroids and pharmaceutical compositions containing them
GB8630913D0 (en) * 1986-12-24 1987-02-04 Glaxo Group Ltd Pharmaceutical compositions
JPH0231703A (ja) * 1988-07-22 1990-02-01 Sukai:Kk 口紅付きリップブラシ
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
YU48707B (sh) * 1990-03-02 1999-07-28 Glaxo Group Limited Aparat za inhaliranje - inhalator
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
DK0617610T3 (da) * 1991-12-18 1997-10-06 Minnesota Mining & Mfg Suspensionsaerosolformuleringer.
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
NZ306281A (en) * 1995-04-14 1999-07-29 Glaxo Wellcome Inc Metered dose inhaler with part or all internal surfaces coated with fluorocarbon polymers for dispensing beclomethasone dipropionate
ATE250439T1 (de) * 1995-04-14 2003-10-15 Smithkline Beecham Corp Dosierinhalator für salmeterol
BR9604976A (pt) * 1995-04-14 1998-06-09 Glaxo Wellcome Inc Inalador de dose medida sistema inalador de dose medida e uso do mesmo
ES2276736T3 (es) 1995-04-14 2007-07-01 Smithkline Beecham Corporation Inhalador medidor de dosis para propionato de flucticasona.
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US20030103906A1 (en) * 1997-10-14 2003-06-05 Smithkline Beecham Corporation Metered dose inhaler having internal surfaces coated with fluorocarbon polymer
US5993782A (en) * 1998-04-28 1999-11-30 Gardner; Conrad O. Therapeutic method for reversing hyposmia in a human patient
US20020133032A1 (en) * 2000-02-25 2002-09-19 Jufang Barkalow Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods
OA12394A (en) 2000-08-05 2004-07-09 Glaxo Group Ltd 6.Alpha-,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl)oxyl-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fuoromethyl ester as an anti-inflammatory agent.
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777400B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US20030207057A1 (en) 2000-09-18 2003-11-06 Britto Ignatius Loy Metered dose inhaler can coated two or more times with fluorocarbon polymers
IL157580A0 (en) * 2001-03-20 2004-03-28 Glaxo Group Ltd Inhalation drug combination
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
EP2039700A2 (fr) * 2001-04-30 2009-03-25 Glaxo Group Limited Nouveaux dérivés androstènes anti-inflammatoires
ATE399174T1 (de) * 2001-06-12 2008-07-15 Glaxo Group Ltd Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003013427A2 (fr) * 2001-08-03 2003-02-20 Smithkline Beecham Corporation Procede de preparation de derives de fluticasone
GB0202564D0 (en) * 2002-02-04 2002-03-20 Glaxo Group Ltd Process
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202563D0 (en) * 2002-02-04 2002-03-20 Glaxo Group Ltd Process
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
WO2004001369A2 (fr) * 2002-06-20 2003-12-31 Sun Pharmaceutical Industries Limited Synthese adaptee de s-fluoromethyl 6$g(a),9$g(a)-difluoro-11$g(b)-hydroxy-16$g(a)-methyl-17$g(a)-propionyloxy-3-oxoandrosta-1,4-diene-17$g(b)-carbothioate
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
WO2004060260A2 (fr) * 2002-12-18 2004-07-22 Glaxo Group Limited Systeme d'administration de medicament dote d'un embout buccal a event
CA2530680A1 (fr) * 2003-04-04 2004-10-14 Alpharma Aps Methode de preparation de derives et d'intermediaires d'acides carbothioiques steroides
MXPA05011225A (es) * 2003-04-18 2005-12-14 Pharmacia & Upjohn Co Llc Politerapias.
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP2007504123A (ja) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害剤
AU2004272077A1 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
EP1526139A1 (fr) * 2003-10-24 2005-04-27 S.N.I.F.F. Italia S.P.A. Procédé pour la préparation d'acides 17-beta-carboxyliques d'androstane et d'esters fluorométhylés de l'acide 17-beta-carboxylique d'androstane de haute pureté
US20070259874A1 (en) * 2003-11-26 2007-11-08 Palle Venkata P Phosphodiesterase Inhibitors
WO2005053647A1 (fr) * 2003-12-03 2005-06-16 Microdrug Ag Produit medical contenant du tiotropium
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
US20060009435A1 (en) * 2004-06-23 2006-01-12 Joseph Kaspi Synthesis and powder preparation of fluticasone propionate
CA2575376A1 (fr) * 2004-07-26 2006-02-02 Chemagis Ltd. Nouvelles formes cristallines d'acide 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-propionyloxy-androsta-1,4-diene-17beta-carboxylique et procede de preparation
PT103202B (pt) 2004-10-19 2011-01-27 Hovione Farmaciencia S A Processo para a esterificação de um ácido carbotiótico
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
NZ566128A (en) 2005-09-02 2011-03-31 Nicox Sa Nitrooxy derivatives of glucocorticoids
WO2007031838A1 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
WO2007045980A1 (fr) * 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de la phosphodiesterase de type iv
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
WO2007070423A2 (fr) * 2005-12-09 2007-06-21 Nycomed Us Inc. Formulations de glucocorticosteroide locales
TWI374147B (en) * 2006-01-27 2012-10-11 Sun Pharma Advance Res Company Ltd Novel 11β-hydroxyandrosta-4-ene-3-ones
AU2013202835B2 (en) * 2006-06-14 2015-11-12 Generics [Uk] Limited Process for the preparation of S-fluoromethyl-6,9-difluoro-11-hydroxy-16-methyl-17-propionyloxy-3-oxo-androsta-1, 4-diene-17-carbothioate and intermediates
AU2007258949B2 (en) * 2006-06-14 2013-02-21 Generics [Uk] Limited Process for the preparation of S-fluoromethyl-6, 9 -difluoro-11 -hydroxy-16 -methyl-17-propionyloxy-3-oxo-androsta-1,4-diene-17 -carbothioate and intermediates
GB0612027D0 (en) * 2006-06-16 2006-07-26 Glaxo Group Ltd Novel process
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
EP2046787B1 (fr) 2006-08-01 2011-04-06 Glaxo Group Limited Composés de pyrazolo[3,4-b]pyridine et leur utilisation en tant qu'inhibiteurs de pde4
WO2008035316A2 (fr) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Inhibiteurs de phosphodiestérase
US20110021473A1 (en) * 2006-09-22 2011-01-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
CA2677838C (fr) 2007-02-11 2017-08-01 Map Pharmaceuticals, Inc. Procede d'administration therapeutique de dhe pour procurer un soulagement rapide de la migraine tout en minimisant le profil des effets secondaires
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
MX2009009793A (es) 2007-03-14 2009-10-16 Ranbaxy Lab Ltd Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa.
NO331891B1 (no) * 2007-03-20 2012-04-30 Clavis Pharma Asa Kjemiske forbindelser, et farmasoytisk preparat inneholdende slike forbindelser, samt anvendelse derav for behandling av kreft, inflammasjon og KOLS
US20080318915A1 (en) * 2007-06-20 2008-12-25 Protia, Llc Deuterium-enriched fluticasone propionate
GB0712454D0 (en) * 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
US8796248B2 (en) 2007-10-05 2014-08-05 Nektar Therapeutics Oligomer-corticosteroid conjugates
EP2111861A1 (fr) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions d'inhibiteurs de type IV de la phosphodiestérase
US7935837B2 (en) * 2008-04-30 2011-05-03 Corum Inc. Process for synthesis of androstane 17-β carbothioic acid and relative compounds thereof
US8642069B2 (en) * 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
EP2376481B1 (fr) 2009-01-13 2013-08-07 Glaxo Group Limited Dérivés de pyrimidine carboxamide comme inhibiteurs de la kinase syk
TWI695723B (zh) 2009-05-29 2020-06-11 美商沛爾醫療股份有限公司 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
ES2742525T3 (es) 2009-10-01 2020-02-14 Adare Pharmaceuticals Us L P Composiciones de corticosteroides administradas oralmente
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
EP2528600B1 (fr) 2010-01-28 2016-06-29 Mahmut Bilgic Composition pharmaceutique de poudre sèche comprenant le tiotropium et le fluticasone
WO2011093811A2 (fr) 2010-01-29 2011-08-04 Mahmut Bilgic Préparations pharmaceutiques comprenant du formotérol et du fluticasone
TR201000685A2 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.
TR201000733A2 (tr) 2010-02-02 2011-08-22 Bi̇lgi̇ç Mahmut Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
WO2011136753A1 (fr) 2010-04-26 2011-11-03 Mahmut Bilgic Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
WO2011141929A2 (fr) 2010-05-11 2011-11-17 Cadila Healthcare Limited Compositions pharmaceutiques aqueuses de fluticasone et d'olopatadine
JP2013536835A (ja) * 2010-09-01 2013-09-26 カディラ・ヘルスケア・リミテッド プロピオン酸／フロ酸フルチカゾンを調製するための方法
HUE034570T2 (en) 2010-10-27 2018-02-28 Hovione Int Ltd Electrophilic reagents for mono-gene methylation, their preparation and use
CN102558273B (zh) 2010-12-14 2014-07-02 浙江省天台县奥锐特药业有限公司 氟替卡松糠酸酯的制备方法
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
US20150165037A1 (en) 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
WO2014007781A2 (fr) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions d'inhalation
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US20140275517A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
ES2664019T3 (es) 2013-05-28 2018-04-18 Sun Pharma Advanced Research Company Limited Métodos para el tratamiento de afecciones inflamatorias mediante el uso de s-[4-(3-fluoro-3-metilbutiriloxi) but-2-inil]6alfa, 9alfa-difluoro-17alfa-(furan-2-il) carboniloxi-11beta -hidroxi-16alfa-metil-3-oxoandrosta-1,4-dieno-17beta -carbotioato
US20160129207A1 (en) 2013-06-17 2016-05-12 Arven Ilac Sanayi Ve Ticaret A.S. Inhalation composition filling method
WO2015034678A2 (fr) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticostéroïde contenant des compositions de comprimés se désintégrant par voie orale pour œsophagite à éonisophiles
US9796750B2 (en) 2014-02-07 2017-10-24 Mylan Laboratories Ltd. Process for the purification of fluticasone propionate using a ketone solvent and water as anti-solvent
US9303060B1 (en) 2014-10-03 2016-04-05 Amphaster Pharmaceuticals, Inc. Methods of preparing intermediate of fluticasone propionate
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
CN110698530A (zh) * 2019-10-30 2020-01-17 山东赛托生物科技股份有限公司 一种丙酸氟替卡松的合成方法
KR20240042438A (ko) 2021-07-09 2024-04-02 아스트라제네카 파마수티컬스 엘피 에어로졸 약물 전달을 위한 조성물, 방법 및 시스템
WO2023119093A1 (fr) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, procédés et systèmes d'administration d'un médicament en aérosol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636010A (en) * 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids
US3828080A (en) * 1972-01-20 1974-08-06 Glaxo Lab Ltd Androstane-17beta-carboxylic acids and processes for the preparation thereof
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
US4188385A (en) * 1978-04-05 1980-02-12 Syntex (U.S.A.) Inc. Thioetianic acid derivatives

Also Published As

Publication number Publication date
JPS56138200A (en) 1981-10-28
ZA81976B (en) 1982-07-28
JPS6337120B2 (fr) 1988-07-22
ECSP941097A (es) 1995-01-16
US4335121A (en) 1982-06-15
PH24267A (en) 1990-05-29
ZW18081A1 (en) 1981-10-21
CA1201114A (fr) 1986-02-25

Similar Documents

Publication Publication Date Title
BE887518A (fr) Cartothioates d'androstanes
BE875773A (nl) 2'deoxy-5-(halogeenvinyl)-uridines
TR21767A (tr) N-fenilsulfonil-n'-pirimidinil-ve-triazinilureler
BE879683A (fr) Strijkpapierbekledingsmassa's met hoge vaste-stofconcentratie
LT2397B (lt) Dantu iklotu sudetis
DK163246C (da) 4'-keto-n-trifluoracetyldaunorubicin
BE876123A (fr) Installation d'ascenseur
ATE202T1 (de) 2-cycloalkyl-pyrimidin(5)
DE3141464A1 (de) "kopiergeraet"
FR2427285B1 (fr) Installation d'ascenseur
BE876795A (fr) Installation d'ensachage
BE876388A (fr) Installation d'ascenseur
BE896957A (fr) Vecteur d'expression
BE893837A (fr) Vecteurs d'expression
IT1157288B (it) Agenti anti-obesita'
LU81071A1 (fr) Vitrai 12
FI790141A (fi) 2 6-dinitrobensenaminer
IT1124914B (it) Procedimento per prevenire l'imbrattamento di elettrodi
BE883955A (fr) "limnimetre"
BE885171A (fr) Installation d'acenseur
NO822578L (no) Tilhengerfeste
BE883954A (fr) "spanningsverzorgingsschakeling"
RO84326A (fr) Compresseur d'agent frigorigene
IT7866310A0 (it) Tiche'
DK139578A (da) Brandhaemmende midler

Legal Events

Date Code Title Description
CCPA Application for a supplementary protection certificate

Free format text: 094C0001

CCPV Grant of a supplementary protection certificate

Free format text: 094C0001, EXPIRES 20050308

RE20 Patent expired

Owner name: GLAXO GROUP LTD

Effective date: 20010213

CCRE Expiry of a supplementary protection certificate

Free format text: PRODUCT NAME FLUTICASONE PROPIONATE (MICRONISE); NAT. REG. NO/DATE 276 S 660 F 11/19931202; FIRST REG GB/PL0045/0153 19900308

Spc suppl protection certif: 94C0001

Filing date: 19951031

Expiry date: 20010213

Extension date: 20050308

CCRE Expiry of a supplementary protection certificate

Free format text: PRODUCT NAME: FLUTICASONE PROPIONATE (MICRONISE); NAT. REG.: 276 S 660 F 11 19931202;FIRST REG.: GBPL0045/0153 19900308

Spc suppl protection certif: 94C0001

Filing date: 19940119

Expiry date: 20010213

Extension date: 20050308